Bayesian Capital Management’s Clover Health Investments CLOV Stock Holding History

Bayesian Capital Management’s Portfolio CLOV Stock Details CLOV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11,716	Closed	-$36.9K	–	657
2024 Q4	$36.9K	Sell	11,716 -25,600	-69%	-$91.5K	﹤0.01%	640
2024 Q3	$105K	Buy	+37,316	New	+$85.4K	0.01%	602
2024 Q2	–	Sell	-179,000	Closed	-$142K	–	792
2024 Q1	$142K	Buy	+179,000	New	+$163K	0.01%	689
2023 Q4	–	Sell	-62,900	Closed	-$67.9K	–	790
2023 Q3	$67.9K	Sell	62,900 -9,000	-13%	-$10.7K	0.01%	628
2023 Q2	$64.5K	Buy	+71,900	New	+$63.8K	0.01%	720
2022 Q3	–	Sell	-75,100	Closed	-$161K	–	738
2022 Q2	$161K	Sell	75,100 -136,400	-64%	-$363K	0.03%	647
2022 Q1	$751K	Buy	211,500 +179,200	+555%	+$520K	0.11%	267
2021 Q4	$120K	Buy	+32,300	New	+$198K	0.04%	336
2021 Q2	–	Sell	-28,300	Closed	-$214K	–	446
2021 Q1	$214K	Buy	+28,300	New	+$319K	0.05%	443

Other funds holding CLOV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bayesian Capital Management's CLOV Position: Q1 2025 in Review

Bayesian Capital Management sold out of Clover Health Investments (CLOV) in Q1 2025, closing a stake of 11,716 shares — an estimated $36.9K sold.

Bayesian Capital Management first reported a position in CLOV in Q1 2021 and held it in 9 quarters. The position peaked at $751K in Q1 2022. 202 funds tracked by Wall St. Rank hold CLOV as of Q1 2025.

Bayesian Capital Management reported no remaining Clover Health Investments position as of Q1 2025 after selling out during the quarter.
Bayesian Capital Management sold 11,716 Clover Health Investments shares in Q1 2025, an estimated $36.9K.
Bayesian Capital Management first reported a position in Clover Health Investments in Q1 2021 and held it in 9 quarters.
Bayesian Capital Management's Clover Health Investments position peaked at $751K in Q1 2022.
202 funds tracked by Wall St. Rank held Clover Health Investments as of Q1 2025.

Based on Bayesian Capital Management's 13F filing for Q1 2025, filed 15 May 2025.